Nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone in advanced gastric or gastro-oesophageal junction cancer: the CheckMate 649 phase 3 trial
The CheckMate 649 phase 3 trial evaluated the efficacy of nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric or gastro-oesophageal junction cancer. The results showed that the combination of nivolumab and chemotherapy or nivolumab and ipilimumab led to significant improvements in overall survival and progression-free survival compared to chemotherapy alone. The combination therapies also had manageable safety profiles. These findings suggest that the combination of nivolumab and chemotherapy or nivolumab and ipilimumab could be a new standard of care for patients with advanced gastric or gastro-oesophageal junction cancer.